1. Introduction {#sec1-bioengineering-05-00058}
===============

Prostate cancer is the most common non-cutaneous neoplasia in western countries, affecting up to one in five individuals, with incidence increasing with age \[[@B1-bioengineering-05-00058]\]. Depending on initial staging, a variable percentage of these patients will experience progression to castration-resistant prostate cancer, defined as evidence of rising tumor marker in spite of androgen blockade \[[@B2-bioengineering-05-00058]\]. Under these conditions, metastastization to the skeletal system frequently occurs; this process can significantly contribute to morbidity and mortality \[[@B3-bioengineering-05-00058]\]. Once considered as a harbinger of terminal disease, today bone metastases can be treated with a variety of modalities, including anti-androgen, cytotoxic, immune, and radioisotope therapy \[[@B2-bioengineering-05-00058],[@B4-bioengineering-05-00058],[@B5-bioengineering-05-00058],[@B6-bioengineering-05-00058],[@B7-bioengineering-05-00058]\]. Owing to the new therapeutic modalities, survival of mCRPC patients has improved significantly \[[@B8-bioengineering-05-00058]\]. However, skeletal metabolic alterations associated with bone metastases remain the principal prognostic factor \[[@B9-bioengineering-05-00058]\]. The presence and extension of bone metastases are easily investigated with imaging methods \[[@B10-bioengineering-05-00058]\]: these techniques include the identification of increased mineral density (at X-ray computed tomography), of bone turnover (afforded by bone scan or by fluoride PET/CT), as well as the characterization of the prostate-specific transmembrane antigen using PSMA-PET. While these methods can identify the characteristics associated with the presence of bone metastases, an accurate estimation of the total tumor burden is challenging, especially in patients with extensive metastastization. An exact quantification of this parameter, expressed as total volume of metastatic tissue or as a percentage of normal trabecular bone occupied by metastases, could help in prognostic stratification as well as in monitoring the therapeutic effectiveness. Over the course of the last decade, many attempts have been carried out to estimate this parameter by applying a computational algorithm to the clinical images (whether scintigraphic or X-ray based). In this review, we are going to analyze the computational methods currently available or in development, to identify the advantages and the disadvantage of each one of them, in order to clarify which of these methods is the most promising for current mCRPC patient care.

2. Methods {#sec2-bioengineering-05-00058}
==========

2.1. Search Strategy {#sec2dot1-bioengineering-05-00058}
--------------------

A computerized literature search of the PubMed/Medline was conducted. A search algorithm, based on a combination of these terms: "metastatic castration-resistant prostate cancer" OR "metastatic CRPC" AND "computational analysis" OR "bone automated analysis" OR "bone tumor burden" OR "bone tumor volume". This search comprised articles published in English in the last decade, i.e., between 2008 and 2018. This choice was motivated by the need to describe the current development in computational analysis and to focus on the currently used methods, also considering the current and constantly evolving computational capabilities of the actual devices.

The search was expanded by manually reviewing the reference list of the chosen articles.

2.2. Study Selection {#sec2dot2-bioengineering-05-00058}
--------------------

Studies or study subset, which investigated the role of computational/automated analysis of CT, SPECT/CT, or PET/CT images in identifying and quantifying bone metastases from CRPC, were included. The following articles were excluded: (I) articles outside the field of interest of the current review; (II) editorials, letters, or conference proceedings; (III) case reports; (IV) phantom, simulation, and/or preclinical studies. Titles and abstract were first screened; in case of unequivocal ineligibility the article was rejected. The full text of the articles that passed this screening process was then assessed to determine its eligibility. In these selected papers, a thorough evaluation of the references was conducted, to identify potential further studies.

The selection process is outlined in [Figure 1](#bioengineering-05-00058-f001){ref-type="fig"}.

2.3. Article Categorization {#sec2dot3-bioengineering-05-00058}
---------------------------

For each selected article, information was collected about the following parameters: basic information (journal, year of publication, author names and country of origin, study type); technical characteristics (type of device used, type of performed analysis, planar or 3D imaging, type of tracer etc.), and finally patients' data (number of enrolled patients, mean age, average Gleason and prevalence of "high risk" patients, mean PSA level).

3. Results and Discussion {#sec3-bioengineering-05-00058}
=========================

3.1. General Parameter {#sec3dot1-bioengineering-05-00058}
----------------------

In total, 35 studies were identified. The main studies parameters are listed in [Table 1](#bioengineering-05-00058-t001){ref-type="table"} and in [Figure 2](#bioengineering-05-00058-f002){ref-type="fig"}. Twenty-five studies (72%) were single-institution, nine studies (25%) were multi-institution, and one was a review \[[@B11-bioengineering-05-00058]\].

The number of eligible studies increased over time, indicating a growing interest in the subject of automated analysis of tumor burden ([Figure 1](#bioengineering-05-00058-f001){ref-type="fig"}). Most single-institution studies (n = 9/25, 36%) originated from the United States; moreover, most of the multi-institutional studies included an American center (n = 6/9, 67%) \[[@B12-bioengineering-05-00058],[@B13-bioengineering-05-00058],[@B14-bioengineering-05-00058],[@B15-bioengineering-05-00058],[@B16-bioengineering-05-00058],[@B17-bioengineering-05-00058],[@B18-bioengineering-05-00058],[@B19-bioengineering-05-00058],[@B20-bioengineering-05-00058],[@B21-bioengineering-05-00058],[@B22-bioengineering-05-00058]\]. Five studies originated from Germany \[[@B23-bioengineering-05-00058],[@B24-bioengineering-05-00058],[@B25-bioengineering-05-00058],[@B26-bioengineering-05-00058],[@B27-bioengineering-05-00058]\], four from Sweden \[[@B28-bioengineering-05-00058],[@B29-bioengineering-05-00058],[@B30-bioengineering-05-00058],[@B31-bioengineering-05-00058]\], and six from Japan \[[@B32-bioengineering-05-00058],[@B33-bioengineering-05-00058],[@B34-bioengineering-05-00058],[@B35-bioengineering-05-00058],[@B36-bioengineering-05-00058],[@B37-bioengineering-05-00058]\]. Information about patient number, acquisition technique, type of employed isotope (when applicable) and method of computational analysis were obtainable from all studies. Seven studies (21%) did not include information about mean patients' age; one did not specify the enrollment method. Twenty-five studies (73%) provided the mean PSA level at the time of scan; only seven (21%) allowed obtaining information about the "high risk" status.

Mean age was very consistent across the studies, ranging from 65 to 75 years. Conversely, PSA levels were very heterogenous, probably because of different clinical protocols and disease aggressiveness. Studies conducted in the US utilized mostly 18F-NaF PET/CT, where this tracer was "re-discovered" following the spread of hybrid PET/CT imaging \[[@B46-bioengineering-05-00058]\]. In Germany, most studies were focused on 68Ga-PSMA-PET/CT, as there is a long-standing history of development and theranostic use of this tracer \[[@B47-bioengineering-05-00058]\]. In Sweden, studies using an artificial neural network method, applied to 2D bone scintigraphies (EXINI bone scan, EXINI Diagnostics, Lund, Sweden) prevailed \[[@B28-bioengineering-05-00058]\]; a similar situation is observed in Japan, where a version of this tool, based on a custom database (BONENAVI, FUJIFILM RI Pharma, Tokyo, Japan), is marketed \[[@B32-bioengineering-05-00058]\].

3.2. Types of Computational Approaches {#sec3dot2-bioengineering-05-00058}
--------------------------------------

Our literature research shows that the problem of skeletal tumor volume quantification in metastatic mCRPC has been tackled using different methods. For the purpose of the current review, we sorted these approaches in four different categories: 2D bone scan segmentation, 3D segmentation based on SUV threshold, 3D segmentation based on CT data or on CT/SUV integration, and MR-based or non-isotope-based methods. Each of these methods presents its own advantages and limitations; in the following parts we are going to discuss them in detail. An overview of the methods' characteristics can be found in [Table 2](#bioengineering-05-00058-t002){ref-type="table"}.

### 3.2.1. Automated 2D Analysis of Bone Scans {#sec3dot2dot1-bioengineering-05-00058}

This computational technique utilizes an automated analysis of tracer distribution, based on a neural network, to identify and quantify bone metastases on planar bone scintigraphies automatically \[[@B32-bioengineering-05-00058],[@B38-bioengineering-05-00058]\]. It proceeds by comparing the selected scan to those present in its database to tell apart tumor-related uptakes from the physiological tracer distribution. This algorithm should in fact allow isolating the signal of metastases from normal structures (urinary bladder, kidneys, etc.). The program can also provide an estimate, the bone scan index (BSI) which represents the percentage of available intraosseous space invaded from metastases. The software application can be also re-trained with different, region-specific databases; to this date two main versions are available: the EXINI bone scan (EXINI Diagnostics, Lund, Sweden), which was calibrated with scan obtained from Swedish patients \[[@B28-bioengineering-05-00058]\] and the BONENAVI system (FUJIFILM RI Pharma, Tokyo, Japan), trained with scintigraphies from Japanese individuals \[[@B32-bioengineering-05-00058]\].

Over the course of years, BSI has been used to estimate the total tumor burden and to predict the patients' clinical course. An early report from Sadik and colleagues indicated that the use of this system increased the sensitivity and the percent of agreement of the reporting physicians \[[@B28-bioengineering-05-00058]\]. A later paper by Takahashi indicated that the automated method works at best with manual corrections from the reader \[[@B32-bioengineering-05-00058]\]. A work by Meirelles observed how BSI is a strong predictor of survival in mCRPC patients; but so was 18F-FDG, probably as a measure of tumor de-differentiation and aggressiveness \[[@B39-bioengineering-05-00058]\]. Mitusi and Dennis showed that a decrease of BSI after therapy was predictive of survival \[[@B35-bioengineering-05-00058],[@B40-bioengineering-05-00058]\]; Reza showed that BSI changes predicted progression-free survival in patients treated with the novel anti-androgen Darolutamide \[[@B41-bioengineering-05-00058]\]. Parallelly, Anand and colleagues analyzed the correlation between BSI and enzalutamide response \[[@B21-bioengineering-05-00058]\]. In a paper from the group of Kaboteh, a strong association between BSI, appearance of new lesions and two-years survival was demonstrated \[[@B31-bioengineering-05-00058]\]. Furthermore, a correlation was observed between BSI and diverse bone turnover markers \[[@B33-bioengineering-05-00058]\]. The paper by Armstrong et al. indicated a correlation between imaging and biochemical markers as well as a strong association between bone-related imaging index and survival \[[@B22-bioengineering-05-00058]\]. A further survival analysis was performed in the work by Uemura \[[@B36-bioengineering-05-00058]\], where BSI was pitted against other potential survival predictors and showed a significant discriminatory power.

The paper from Miederer was the first paper investigating the correlation between BSI and insurgence of hematologic toxicity in a group of mCRPC treated with 223-RaCl~2~ \[[@B27-bioengineering-05-00058]\]. Remarkably, the incidence of toxicity reported by this paper is significantly higher than the one described in the larger validation trials; this is likely to depend from the greater tumor load in his patient population. On the same line, the work by the group of Alva identified the group of patients with BSI \< 5 as optimal candidates for the 223RaCl~2~ therapy, as these were more likely to be able to receive the entire course of six cycles of the bone-seeking alpha-emitter \[[@B20-bioengineering-05-00058]\]. Recently, Fosbøl and co-worker confirmed the capability of BSI to predict both overall survival and hematologic toxicity in a larger series \[[@B42-bioengineering-05-00058]\].

In the work from Shintawati and co-workers, BSI was evaluated on bone scan acquired at different time points after injection \[[@B34-bioengineering-05-00058]\]. The index increased significantly from 2 h p.i. up to 4 h and again in the late 6 h scan; the variation was greatest in the pelvic segment. In the process, some physiological uptakes were sometimes misclassified as lesions at different time points. The authors conclude that the acquisition time should be standardized and that the neural network should be again trained with scans acquired at that specific time point.

Finally, a work by Thomas et al. compared BSI, visual analysis and 68-Ga-PSMA-PET/CT: the latter was able to detect more lesions \[[@B25-bioengineering-05-00058]\]. However, no changes in clinical management would have resulted from the improved detection.

In general, the advantages linked with this method are the easiness of use, the prompt availability of an easy to interpret score, the wide diffusion of bone scintigraphy as an imaging method, and its reproducibility \[[@B34-bioengineering-05-00058]\]. The disadvantages of such an approach lay in the bidimensional nature of the bone scan and in the lack of specificity of the method. In fact, there is no established uptake threshold that can distinguish benign from metastatic uptake on planar scintigraphy: for this reason, fractures, degenerative joint disease, overlapping renal uptake, benign cartilage calcifications, Paget's disease, and many more instance could all be misclassified as tumor volume, especially when in proximity or overlapping with metastatic foci. All these instances need to be manually corrected by the operator; however, the necessary level of certainty to make such corrections can only be achieved by integrating the scan with SPECT imaging or by resorting to a co-registered/recent CT.

Moreover, if the system is trained on a specific population, it might not function properly when applied to a different one. In fact, Takahashi and co-workers reported a significant increase in specificity when using a program that was trained specifically for the local population when compared to a software application trained with a foreign one. The authors attributed this phenomenon to a difference in the average physical constitution, which causes a different photon attenuation that cannot be compensated in the absence of transmissive information.

Finally, if used to perform longitudinal evaluations, the method could be misguided by the so-called "flare" reaction, represented by a temporary an increase of activity within the bone localizations, which then is followed by a radiological response \[[@B48-bioengineering-05-00058]\].

### 3.2.2. SUV-Based Thresholding {#sec3dot2dot2-bioengineering-05-00058}

This method is applied to PET (or possibly to quantitative SPECT) and utilizes a definite standardized uptake value (SUV) cutoff to calculate the volume of tissue with high tracer uptake, which is supposed to be expression of metastatic involvement. Many tracers were tested with this method: 18F-NaF \[[@B14-bioengineering-05-00058],[@B30-bioengineering-05-00058]\], 11C-Choline \[[@B12-bioengineering-05-00058],[@B19-bioengineering-05-00058]\], and 68Ga-PSMA \[[@B24-bioengineering-05-00058]\]; it has the advantages of affording a 3D evaluation, thus eliminating the overlap artifacts, and to be relatively easy and speedy to employ. Moreover, whenever a co-registered CT or MR is available, the specificity of the method is significantly higher, as the operator can use the morphological data to eliminate all the uptake source that may not be related to tumor manifestations manually.

Similarly to BSI, PET-based tumor volume segmentation was used to predict the patients' clinical outcome. The earliest work that used this approach dates to 2014, when Kwee and colleagues calculated tumor volume and activity on a series of 11C-Choline scans \[[@B12-bioengineering-05-00058],[@B19-bioengineering-05-00058]\]. These parameters strongly correlated with PSA level and were able to predict survival at univariate survival analysis. The same group used the same index to assess treatment response (a variety of therapeutic modalities were employed) and concluded that automated analysis could be relevant in predicting therapy outcome and thus play a role in personalized medicine Later on, a group at Texas University established a SUV threshold for tumor volume in fluoride PET and used this value to predict overall survival, hematologic toxicity, and skeletal-related events \[[@B14-bioengineering-05-00058],[@B15-bioengineering-05-00058],[@B18-bioengineering-05-00058]\]. In 2017, a paper by Wassberg demonstrated the repeatability of NaF-derived volumetric parameters \[[@B30-bioengineering-05-00058]\].

A recent a large series by Schmuck, Derlin, and co-workers translated the concept of 3D segmentation onto the PSMA-based PET imaging \[[@B24-bioengineering-05-00058]\]. Here, the authors demonstrated a very tight correlation between 68-Ga-PSMA based tumor volume and circulating PSA levels, moreover, volumetric parameters predicted therapy efficacy.

Lastly, a recent work by Umeda et al. used quantitative SPECT to establish a SUV threshold, which was used to discriminate metastases from degenerative changes and to compute a "total bone uptake" as a measure of tumor burden \[[@B37-bioengineering-05-00058]\]. This value was compared to BSI and resulted slightly more efficient in assessing presence of disease a therapy response.

In PET- and SPECT-based segmentation, an accurate standardization is needed, since SUV is dependent from different factors, like image acquisition and data reconstruction, VOI definition, tracer-specific pathophysiological factors, or the kinetics of tracer distribution. Even in single-center studies, SUV can show relevant variation over the years, as the detectors' sensitivity dwindles \[[@B49-bioengineering-05-00058]\]. Besides, the adoption of a fixed threshold does not in any way ensure a full specificity of the segmented uptake (as SUV of many benign processes overlaps with the metastases-related one) \[[@B50-bioengineering-05-00058]\]; increasing this threshold might result in a loss of sensitivity while decreasing it might affect specificity. In general, SUV-based analyses share the limitations of bone scan evaluations, since the risk of establishing an inadequate threshold cannot be fully eliminated. However, the 3D nature and the presence of co-registered morphological imaging can help the reader in correcting such automated evaluations. Moreover, the adoption of more specific tracers, such as 68Ga- or 18F-PSMA can increase the methods specificity when compared to bene-seeking tracers, thus allowing for a more confident application of this method.

### 3.2.3. Hybrid CT- and SUV-Based Thresholding {#sec3dot2dot3-bioengineering-05-00058}

In order to overcome the limitations of uptake threshold techniques, hybrid analysis techniques have been developed in the last few years \[[@B13-bioengineering-05-00058],[@B16-bioengineering-05-00058],[@B17-bioengineering-05-00058],[@B23-bioengineering-05-00058],[@B26-bioengineering-05-00058]\]. These methods are applied to multi-modal imaging (PET/CT or SPECT/CT) and use the information from both the morphologic and the functional dataset to define the tumor volume accurately. The advantage of this approach is the high degree of accuracy: for instance, the methodic proposed by Bieth and colleagues \[[@B23-bioengineering-05-00058]\] starts by recognizing the bone and by eliminating all the soft tissue; then, it uses a PET-based segmentation to identify the uptakes within the bone volume. As PSMA uptake in bone is considered to be very specific and all external PSMA sources have been taken out, it results that this method can provide a very accurate reading of bone tumor volume. Another approach, developed by our group on the basis of a bone marrow segmentation application \[[@B26-bioengineering-05-00058],[@B51-bioengineering-05-00058],[@B52-bioengineering-05-00058],[@B53-bioengineering-05-00058],[@B54-bioengineering-05-00058]\], utilizes a CT-based adaptive threshold algorithm to discriminate between normal trabecular bone and metastases. These CT-based volumes are then translated onto the co-registered functional (PET or SPECT) images \[[@B26-bioengineering-05-00058]\].

Using this method, the program can provide both CT- and SPECT/PET-based information, which may be correlated with clinical and laboratory parameter. In this study, we observed how metabolic intensity in trabecular bone and tumor volume are predictor of hematologic toxicity in patients treated with 223RaCl~2~ therapy.

Other hybrid methods include the one proposed by Yip \[[@B13-bioengineering-05-00058]\], who employed an articulated registration to segment bone lesions on 18F-NaF-PET/CT scans. This method performed better than rigid and deformable algorithms. Harmon et al. also segmented bone lesion using an SUV threshold, after having sorted out all non-osseous tissue by using a CT-based mask \[[@B17-bioengineering-05-00058]\]. Their result demonstrated how imaging-grounded metrics (including tumor burden, SUVtotal, and SUVmean) outperformed clinical parameters in predicting progression-free survival. Finally, the group led by Lindgren Belal compared two methods of hybrid segmentation (semi-automatic and manual) to BSI \[[@B29-bioengineering-05-00058]\]. The three methods were equally effective in predicting overall survival.

Generally, these 'hybrid' methods can potentially produce more reliable results than the ones based on counts or SUV thresholding, since they start by defining the target bone region, thus excluding many confounding uptake sources (such as the urinary system). Moreover, they can produce a large quantity of potentially useful information, including morphological parameters such as density and volume as well as functional ones such as uptake intensity. They are however relatively complicated and not completely suitable to everyday practice, as the analysis is complex, requiring a certain amount of training and necessitating a relevant computational power or a long elaboration time. For these reasons, such methods are presently more appropriate for research applications.

### 3.2.4. MR-Based and other Non-Isotopic Methods {#sec3dot2dot4-bioengineering-05-00058}

Magnetic resonance imaging (MRI) is actually a powerful tool in detection of tumor burden in mCRPC. However, due to the long acquisition time of whole-body imaging and the concerns due to patients' discomfort, it is only rarely used in staging and re-staging of these patients. Nonetheless, new acquisition techniques, able to speed up the scan process, and the rise of hybrid PET/MR system could signify an important role for MRI in mCRPC. Accordingly, techniques used to estimate the osseous tumor burden in MRI are in course of development. Blackledge et al. devised a semi-automatic method, in which the operator adjusted a threshold parameter to delimit the tumor localizations \[[@B43-bioengineering-05-00058]\]. In this volume, a probabilistic model is applied to reduce the misclassified voxels. In the whole patient population, subjects who responded to treatment displayed a greater global apparent diffusion coefficient than non-responders.

Perez-Lopez and colleagues utilized a semi-automatic segmentation of T1 and diffusion-weighted images to calculate the tumor burden, then they compared these results with BSI \[[@B44-bioengineering-05-00058]\]. Tumor volume and BSI were correlated; furthermore, tumor burden could predict survival and was associated with many clinical and radiological parameters.

Finally, Brisset and colleagues set up a complex study, in which, among other parameters, investigated CT- and MRI-related parameter with a voxel based-analysis \[[@B45-bioengineering-05-00058]\]. Such parameters were able to tell apart stable from progressive disease at a longitudinal analysis.

In general, MRI-based method offer the advantage of excellent lesion contrast and the potential to detect also non-osseous localizations with a high degree of confidence. Moreover, the use of MRI can spare the patients, handling personnel, and general population from radiation exposure. However, whole-body MRI is not yet diffuse due to its relatively long acquisition time and thus, low patient throughput. Although studies on this matter are limited, it remains a promising research path.

4. Conclusions {#sec4-bioengineering-05-00058}
==============

The application of computational analysis methods to planar or hybrid imaging is a constantly growing field of imaging science. In the clinical scenario of metastatic CRPC, whose prevalence has been steadily increasing in recent years, it could improve patients management by allowing an accurate quantification of tumor load and produce a reliable index to test the therapeutic effectiveness of the many new treatment methods. Moreover, it has the potential to turn the everyday scan in a plentiful source of information, which can non-invasively disclose a great quantity of information on tumor biology as well as on therapy efficacy.

When choosing the most proper approach, it is important to strike a balance between striving for rapid results and avoiding inaccuracy. In this line, it appears that choosing a specific tracer (such as 68Ga-PSMA) and using all the available information (including functional and morphologic data) can be helpful in tackling this endeavor and in ensuring the best patient care.
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bioengineering-05-00058-t001_Table 1

###### 

Characteristics of the selected studies.

  First Author     Year   Reference                            Country                    Type of Study   Pts. Number   Techinique             Tracer                        Analysis                                                     Mean Age   Mean Gleason   Mean PSA (ng/mL)   High Risk Ratio
  ---------------- ------ ------------------------------------ -------------------------- --------------- ------------- ---------------------- ----------------------------- ------------------------------------------------------------ ---------- -------------- ------------------ -----------------
  NAKAJIMA         2017   \[[@B11-bioengineering-05-00058]\]   JAPAN/SWEDEN               RW              \-            \-                     \-                            REVIEW                                                       \-         \-             \-                 \-
  KWEE             2014   \[[@B12-bioengineering-05-00058]\]   USA                        P               30            PET/CT                 18F-CHOLINE                   PET-BASED SEGMENTATION                                       73         N/A            35.1               N/A
  YIP              2014   \[[@B13-bioengineering-05-00058]\]   USA                        NS              16            PET/CT                 18F-FLUORIDE                  HYBRID CT- AND PET-BASED SEGMENTATION                        69         N/A            N/A                N/A
  ETCHEBEHERE      2015   \[[@B14-bioengineering-05-00058]\]   USA                        R               42            PET/CT                 18F-FLUORIDE                  PET-BASED SEGMENTATION                                       71.7       N/A            54                 64.3%
  ROHREN           2015   \[[@B15-bioengineering-05-00058]\]   USA                        R               68            PET/CT                 18F-FLUORIDE                  PET-BASED SEGMENTATION                                       65.7       N/A            N/A                N/A
  LIN              2016   \[[@B16-bioengineering-05-00058]\]   USA                        P               35            PET/CT                 18F-FLUORIDE                  HYBRID CT- AND PET-BASED SEGMENTATION                        71.5       7.8            49                 41%
  HARMON           2017   \[[@B17-bioengineering-05-00058]\]   USA                        P               58            PET/CT                 18F-FLUORIDE                  HYBRID CT- AND PET-BASED SEGMENTATION                        71         N/A            N/A                48%
  ETCHEBEHERE      2016   \[[@B18-bioengineering-05-00058]\]   USA/BRASIL                 R               41            PET/CT                 18F-FLUORIDE                  PET-BASED SEGMENTATION                                       71         N/A            150                61.9%
  LEE              2016   \[[@B19-bioengineering-05-00058]\]   SOUTH KOREA/USA            P               42            PET/CT                 18F-CHOLINE                   PET-BASED SEGMENTATION                                       73         N/A            329                N/A
  ALVA             2017   \[[@B20-bioengineering-05-00058]\]   USA/SWEDEN                 R               145           BONE SCAN              99mTc-DPD                     EXINI BONE SCAN ANN                                          71.8       9              188.7              70%
  ANAND            2016   \[[@B21-bioengineering-05-00058]\]   USA/SWEDEN                 R               80            BONE SCAN              99mTc-MDP                     EXINI BONE SCAN ANN                                          71         N/A            157.5              N/A
  ARMSTRONG        2014   \[[@B22-bioengineering-05-00058]\]   USA/SWEDEN                 R               85            BONE SCAN              NOT SPECIFIED \*              EXINI BONE SCAN ANN                                          N/A        N/A            N/A                N/A
  BIETH            2017   \[[@B23-bioengineering-05-00058]\]   GERMANY                    R               45            PET/CT                 68-Ga-PSMA                    HYBRID CT- AND PET-BASED SEGMENTATION                        71         N/A            43                 N/A
  SCHMUCK          2017   \[[@B24-bioengineering-05-00058]\]   GERMANY                    R               101           PET/CT                 68-Ga-PSMA                    PET-BASED SEGMENTATION                                       69.1       7 \*\*\*       4.1                N/A
  THOMAS           2017   \[[@B25-bioengineering-05-00058]\]   GERMANY                    R               30            BONE SCAN AND PET/CT   99mTc-MPD AND 68-Ga-PSMA      EXINI BONE SCAN ANN; VISUAL ANALYSIS                         N/A        N/A            N/A                N/A
  FIZ              2017   \[[@B26-bioengineering-05-00058]\]   GERMANY/ITALY              R               47            BONE SPECT/CT          99mTc-DPD                     CT-BASED SEGMENTATION                                        69.5       8              788                68%
  MIEDERER         2015   \[[@B27-bioengineering-05-00058]\]   GERMANY                    R               14 \*\*       BONE SCAN              99mTc-DPD                     EXINI BONE SCAN ANN                                          71         N/A            N/A                N/A
  SADIK            2009   \[[@B28-bioengineering-05-00058]\]   SWEDEN                     R               41            BONE SCAN              99mTc-MPD                     EXINI BONE SCAN ANN                                          65         N/A            N/A                N/A
  LINDGREN BELAI   2017   \[[@B29-bioengineering-05-00058]\]   SWEDEN                     R               48            BONE SCAN AND PET/CT   99mTc-HPD AND 18-F-FLUORIDE   HYBRID CT- AND PET-BASED SEGMENTATION; EXINI BONE SCAN ANN   73         7.7            374                N/A
  WASSBERG         2017   \[[@B30-bioengineering-05-00058]\]   SWEDEN                     P               10            PET/CT                 18F-FLUORIDE                  PET-BASED SEGMENTATION                                       74.6       8.1            208.5              50%
  KABOTEH          2013   \[[@B31-bioengineering-05-00058]\]   SWEDEN                     R               266           BONE SCAN              99mTc-MDP                     EXINI BONE SCAN ANN                                          76         N/A            N/A                N/A
  TAKAHASHI        2012   \[[@B32-bioengineering-05-00058]\]   JAPAN                      R               158           BONE SCAN              99mTc-MPD                     BONENAVI BONE SCAN ANN                                       69.5       N/A            148                N/A
  WAKABAYASHI      2013   \[[@B33-bioengineering-05-00058]\]   JAPAN                      R               52            BONE SCAN              99mTc-MPD                     BONENAVI BONE SCAN ANN                                       71         9              N/A \*\*\*\*       N/A
  SHINTAWATI       2015   \[[@B34-bioengineering-05-00058]\]   JAPAN                      P               20            BONE SCAN              99mTc-MPD                     BONENAVI BONE SCAN ANN                                       N/A        N/A            N/A                N/A
  MITSUI           2012   \[[@B35-bioengineering-05-00058]\]   JAPAN                      R               42            BONE SCAN              99mTc-MDP                     BONENAVI BONE SCAN ANN                                       73         8              65.3               N/A
  UEMURA           2016   \[[@B36-bioengineering-05-00058]\]   JAPAN                      R               41            BONE SCAN              NOT SPECIFIED \*              BONENAVI BONE SCAN ANN                                       73         N/A            56.8               N/A
  UMEDA            2018   \[[@B37-bioengineering-05-00058]\]   JAPAN                      R               47            BONE SPECT/CT          99mTc-MDP                     SPECT-BASED SEGMENTATION; BONENAVI BONE SCAN ANN             74         N/A            N/A                N/A
  BROWN            2012   \[[@B38-bioengineering-05-00058]\]   USA                        R               20            BONE SCAN              99mTc-MDP                     CAD ANALYSIS                                                 N/A        N/A            N/A                N/A
  MEIRELLES        2010   \[[@B39-bioengineering-05-00058]\]   USA                        P               39            BONE SCAN AND PET/CT   99mTc-HPD AND 18-F-FDG        EXINI BONE SCAN ANN                                          68         N/A            N/A                N/A
  DENNIS           2012   \[[@B40-bioengineering-05-00058]\]   USA                        R               88            BONE SCAN              NOT SPECIFIED \*              EXINI BONE SCAN ANN                                          67.7       8              95.95              N/A
  REZA             2016   \[[@B41-bioengineering-05-00058]\]   SWEDEN/UK/FINLAND/FRANCE   R               47            BONE SCAN              NOT SPECIFIED \*              EXINI BONE SCAN ANN                                          68         N/A            83.1               N/A
  FOSBØL           2018   \[[@B42-bioengineering-05-00058]\]   DENMARK                    R               88            BONE SCAN              NOT SPECIFIED \*              EXINI BONE SCAN ANN                                          71         N/A            212                N/A
  BLACKLEDGE       2014   \[[@B43-bioengineering-05-00058]\]   UK                         P               7             MRI                    NONE                          MARKOV RANDOM FIELD MODEL                                    N/A        N/A            N/A                N/A
  PEREZ-LOPEZ      2016   \[[@B44-bioengineering-05-00058]\]   UK                         R               43            MRI AND BONE SCAN      NOT SPECIFIED \*              MR SEGMENTATION AND EXINI BONE SCAN ANN                      N/A        N/A            43                 N/A
  BRISSET          2015   \[[@B45-bioengineering-05-00058]\]   USA/HOLLAND                P               12            CT AND MR              NONE                          VOXEL-BASED ANALYSIS                                         N/A        N/A            N/A                N/A

LEGEND: R: retrospective; P: prospective; NS: non-specified; RW: review; N/A: not available; ANN: artificial neural network; \* Unspecified 99mTc-labelled diphosphonate; \*\* Included a multicentric survey; \*\*\* Only median value was provided; \*\*\*\* Expressed as log.
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###### 

Advantages and disadvantages of the study types. The table includes also the relative frequency of the described method, when compared to the other ones.

  Method                                                Advantages                                                                                                         Disadvantages                                                                                                            Relative Frequency
  ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------ --------------------------------------------
  Neural network analysis applied to planar bone scan   -Wide diffusion of bone scan-Ease of use-Reproducibility-Prompt readability                                        -Overlap artifacts-Lack of specificity-Frequent need for manual corrections-Need for local databases-"Flare" responses   Common (prevalent diffusion of bone scan)
  PET-based thresholding                                -Relatively easy and prompt application-3D volume definition-High specificity using co-registered CT               -Need for threshold recalibration-Need for active exclusion of non-bone and non-tumor uptakes                            Uncommon
  Hybrid CT- and PET/SPECT-based thresholding           -High accuracy thanks to dual segmentation-High information output suitable for 'big data' research applications   -Computationally intensive-Long elaboration times-Not yet validated for clinical practice                                Rare (presently only research application)
  MR-based and other non-isotopic methods               -Excellent lesion-to-background contrast-No radiation burden to the patient and to the general population          -Whole-body MRI still not diffusely utilized-Need for long acquisition and elaboration time                              Rare (presently only research application)
